Annual EBITDA
-$924.84 M
-$1.19 B-453.78%
31 December 2023
Summary:
Ironwood Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization is currently -$924.84 million, with the most recent change of -$1.19 billion (-453.78%) on 31 December 2023. During the last 3 years, it has fallen by -$1.07 billion (-751.74%). IRWD annual EBITDA is now -453.78% below its all-time high of $261.42 million, reached on 31 December 2022.IRWD EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
$27.30 M
+$443.00 K+1.65%
30 September 2024
Summary:
Ironwood Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization is currently $27.30 million, with the most recent change of +$443.00 thousand (+1.65%) on 30 September 2024. Over the past year, it has dropped by -$14.98 million (-35.44%). IRWD quarterly EBITDA is now -68.55% below its all-time high of $86.79 million, reached on 31 December 2017.IRWD Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
$105.76 M
-$14.98 M-12.41%
30 September 2024
Summary:
Ironwood Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization is currently $105.76 million, with the most recent change of -$14.98 million (-12.41%) on 30 September 2024. Over the past year, it has increased by +$994.76 million (+111.90%). IRWD TTM EBITDA is now -60.84% below its all-time high of $270.07 million, reached on 31 March 2023.IRWD TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IRWD EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -453.8% | -35.4% | +111.9% |
| 3 y3 years | -751.7% | -59.5% | -54.2% |
| 5 y5 years | -540.2% | -19.7% | +66.2% |
IRWD EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -453.8% | at low | -63.9% | +102.5% | -60.8% | +110.8% |
| 5 y | 5 years | -453.8% | at low | -63.9% | +102.5% | -60.8% | +110.8% |
| alltime | all time | -453.8% | at low | -68.5% | +102.5% | -60.8% | +110.8% |
Ironwood Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $27.30 M(+1.6%) | $105.76 M(-12.4%) |
| June 2024 | - | $26.85 M(+118.4%) | $120.74 M(-112.3%) |
| Mar 2024 | - | $12.29 M(-68.7%) | -$980.22 M(+5.9%) |
| Dec 2023 | -$924.84 M(-453.8%) | $39.32 M(-7.0%) | -$925.24 M(+4.1%) |
| Sept 2023 | - | $42.28 M(-103.9%) | -$889.00 M(+3.4%) |
| June 2023 | - | -$1.07 B(-1696.7%) | -$859.88 M(-418.4%) |
| Mar 2023 | - | $67.27 M(-11.0%) | $270.07 M(+3.3%) |
| Dec 2022 | $261.42 M(+12.0%) | $75.57 M(+5.8%) | $261.42 M(+8.2%) |
| Sept 2022 | - | $71.39 M(+27.9%) | $241.63 M(+1.7%) |
| June 2022 | - | $55.84 M(-4.8%) | $237.68 M(-2.6%) |
| Mar 2022 | - | $58.62 M(+5.1%) | $243.94 M(+4.6%) |
| Dec 2021 | $233.31 M(+64.4%) | $55.78 M(-17.3%) | $233.31 M(+1.0%) |
| Sept 2021 | - | $67.44 M(+8.6%) | $231.05 M(+10.9%) |
| June 2021 | - | $62.09 M(+29.4%) | $208.28 M(+16.4%) |
| Mar 2021 | - | $48.00 M(-10.3%) | $179.00 M(+26.1%) |
| Dec 2020 | $141.90 M(+40.3%) | $53.52 M(+19.8%) | $141.90 M(-2.2%) |
| Sept 2020 | - | $44.68 M(+36.2%) | $145.09 M(+8.0%) |
| June 2020 | - | $32.80 M(+200.9%) | $134.38 M(+8.2%) |
| Mar 2020 | - | $10.90 M(-80.8%) | $124.15 M(+22.1%) |
| Dec 2019 | $101.13 M(-170.0%) | $56.70 M(+66.9%) | $101.68 M(+59.8%) |
| Sept 2019 | - | $33.98 M(+50.6%) | $63.63 M(-157.6%) |
| June 2019 | - | $22.56 M(-295.1%) | -$110.56 M(-23.2%) |
| Mar 2019 | - | -$11.57 M(-162.0%) | -$144.00 M(-10.6%) |
| Dec 2018 | -$144.45 M(+2352.9%) | $18.65 M(-113.3%) | -$161.04 M(+73.3%) |
| Sept 2018 | - | -$140.21 M(+1188.8%) | -$92.90 M(-434.1%) |
| June 2018 | - | -$10.88 M(-62.0%) | $27.80 M(+375.0%) |
| Mar 2018 | - | -$28.61 M(-133.0%) | $5.85 M(-202.2%) |
| Dec 2017 | -$5.89 M(-81.2%) | $86.79 M(-545.0%) | -$5.73 M(-94.1%) |
| Sept 2017 | - | -$19.50 M(-40.6%) | -$96.91 M(+1.5%) |
| June 2017 | - | -$32.83 M(-18.3%) | -$95.43 M(+34.6%) |
| Mar 2017 | - | -$40.19 M(+816.1%) | -$70.93 M(+126.6%) |
| Dec 2016 | -$31.30 M | -$4.39 M(-75.7%) | -$31.30 M(+11.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2016 | - | -$18.03 M(+116.6%) | -$28.16 M(-37.0%) |
| June 2016 | - | -$8.32 M(+1394.3%) | -$44.72 M(-40.7%) |
| Mar 2016 | - | -$557.00 K(-55.7%) | -$75.39 M(-24.6%) |
| Dec 2015 | -$99.94 M(-36.0%) | -$1.26 M(-96.4%) | -$99.94 M(-22.0%) |
| Sept 2015 | - | -$34.58 M(-11.3%) | -$128.12 M(+0.9%) |
| June 2015 | - | -$38.99 M(+55.3%) | -$127.04 M(-9.3%) |
| Mar 2015 | - | -$25.11 M(-14.7%) | -$140.07 M(-10.3%) |
| Dec 2014 | -$156.12 M(-35.0%) | -$29.43 M(-12.1%) | -$156.12 M(-8.3%) |
| Sept 2014 | - | -$33.50 M(-35.6%) | -$170.29 M(-10.5%) |
| June 2014 | - | -$52.02 M(+26.4%) | -$190.23 M(-2.6%) |
| Mar 2014 | - | -$41.16 M(-5.6%) | -$195.25 M(-18.7%) |
| Dec 2013 | -$240.08 M(+292.0%) | -$43.61 M(-18.4%) | -$240.08 M(+1.1%) |
| Sept 2013 | - | -$53.44 M(-6.3%) | -$237.51 M(+78.1%) |
| June 2013 | - | -$57.04 M(-33.7%) | -$133.39 M(+16.7%) |
| Mar 2013 | - | -$85.99 M(+109.6%) | -$114.33 M(+86.7%) |
| Dec 2012 | -$61.24 M(+11.8%) | -$41.03 M(-181.0%) | -$61.24 M(+150.1%) |
| Sept 2012 | - | $50.68 M(-233.4%) | -$24.49 M(-73.8%) |
| June 2012 | - | -$37.98 M(+15.4%) | -$93.50 M(+30.6%) |
| Mar 2012 | - | -$32.91 M(+668.1%) | -$71.57 M(+30.0%) |
| Dec 2011 | -$54.79 M(+3.4%) | -$4.28 M(-76.6%) | -$55.07 M(-9.0%) |
| Sept 2011 | - | -$18.33 M(+14.2%) | -$60.50 M(+6.8%) |
| June 2011 | - | -$16.05 M(-2.2%) | -$56.62 M(+0.3%) |
| Mar 2011 | - | -$16.41 M(+68.9%) | -$56.45 M(+6.0%) |
| Dec 2010 | -$53.00 M(-4.0%) | -$9.72 M(-32.8%) | -$53.26 M(-15.4%) |
| Sept 2010 | - | -$14.45 M(-9.0%) | -$62.98 M(+12.9%) |
| June 2010 | - | -$15.87 M(+20.1%) | -$55.80 M(-2.4%) |
| Mar 2010 | - | -$13.22 M(-32.0%) | -$57.16 M(-6.7%) |
| Dec 2009 | -$55.21 M(+6.5%) | -$19.44 M(+167.3%) | -$61.28 M(+17.4%) |
| Sept 2009 | - | -$7.27 M(-57.8%) | -$52.22 M(+16.2%) |
| June 2009 | - | -$17.24 M(-0.6%) | -$44.95 M(+62.2%) |
| Mar 2009 | - | -$17.34 M(+67.1%) | -$27.71 M(+167.1%) |
| Dec 2008 | -$51.85 M(+1.3%) | -$10.38 M | -$10.38 M |
| Dec 2007 | -$51.17 M | - | - |
FAQ
- What is Ironwood Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Ironwood Pharmaceuticals?
- What is Ironwood Pharmaceuticals annual EBITDA year-on-year change?
- What is Ironwood Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Ironwood Pharmaceuticals?
- What is Ironwood Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Ironwood Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Ironwood Pharmaceuticals?
- What is Ironwood Pharmaceuticals TTM EBITDA year-on-year change?
What is Ironwood Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of IRWD is -$924.84 M
What is the all time high annual EBITDA for Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is $261.42 M
What is Ironwood Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, IRWD annual earnings before interest, taxes, depreciation & amortization has changed by -$1.19 B (-453.78%)
What is Ironwood Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of IRWD is $27.30 M
What is the all time high quarterly EBITDA for Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is $86.79 M
What is Ironwood Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, IRWD quarterly earnings before interest, taxes, depreciation & amortization has changed by -$14.98 M (-35.44%)
What is Ironwood Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of IRWD is $105.76 M
What is the all time high TTM EBITDA for Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is $270.07 M
What is Ironwood Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, IRWD TTM earnings before interest, taxes, depreciation & amortization has changed by +$994.76 M (+111.90%)